This trial is testing a study drug (burosumab) to see if it helps people with FD who have low blood phosphate levels. People with FD are prone to deformities, fractures, and other problems. The study will last 48 weeks, and participants will visit the NIH 3 times. They will self-inject the drug at home 1-2 times/month.
1 Primary · 9 Secondary · Reporting Duration: 48 weeks (adults), 50 weeks (children)
15 Total Participants · 1 Treatment Group
Primary Treatment: Burosumab · No Placebo Group · Phase 2
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: